Ribociclib
Advanced Lung Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Advanced Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FULVESTRANT TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 2 | B |
gsk1120212 Sun Yat-sen University | Phase 2 | B |
al2846 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | B |
bnt324 BioNTech SE | Phase 1/2 | CC |
bnt327 BioNTech SE | Phase 1/2 | CC |
View all 11 →
Same molecule, other indications
Ribociclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →